Treatment of Primary Myelofibrosis with Symptomatic Splenomegaly and Platelet Count Below 50×10⁹/L

This page covers a specific and clinically challenging sub-group of primary myelofibrosis: patients who are non-low risk, present with symptomatic splenomegaly and/or constitutional symptoms, and have a platelet count below 50×10⁹/L.

Clinical Scenario

Disease context: Primary myelofibrosis — non-low risk

Presentation: Symptomatic splenomegaly and/or significant disease-related symptoms

Key finding: Platelet count <50×10⁹/L

Patients with platelet counts below 50×10⁹/L are at high risk of bleeding. This low platelet threshold has direct implications for which treatment options can be safely considered in this population.

Treatment Goals

Clinical endpoints include achieving a meaningful reduction in spleen volume and a substantial improvement in total symptom score from baseline at week 24.

Treatment Approach (partial overview)

The approach for this low-platelet sub-group includes a specific agent suitable for use in the context of severe thrombocytopenia, along with other options — see the full regimen for the complete algorithm, sequencing, and criteria.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2022017423

Symptomatic splenomegaly and/or symptoms. Non-low risk. PLT <50×10⁹/L.

Patients with platelets below 50 × 10⁹/L are at high risk of bleeding and should not be considered for standard doses of RUX or FEDR, especially if PAC is available.

PAC, or clinical trials, or HU.

Spleen volume reduction equal to or greater than 35% (SVR35) and total symptom score reduction equal to or higher than 50% (TSS50) from baseline to week 24 were mostly the main end points.

View source ↗